Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
ALMS Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALMS Stock 12 Month Forecast
Average Price Target
$19.60
▲(370.02% Upside)
| Highest Price Target$25.00 | Average Price Target$19.60 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$29→$20
Buy
379.62%
Upside
Assigned
08/15/25
Wells Fargo
$17
Buy
307.67%
Upside
Reiterated
08/15/25
Morgan Stanley
$23→$22
Buy
427.58%
Upside
Reiterated
08/15/25
Cantor Fitzgerald
―
Buy
―
Reiterated
08/14/25
H.C. Wainwright
$14
Buy
235.73%
Upside
Reiterated
08/14/25
Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic PositioningValuation and Risks. Using a discounted cash flow (DCF)-based approach, we derive a firm value of $1.7B and a 12- month price objective of $14 per share, which includes the estimated end-2Q26 cash position of ~$262M and ~115M shares outstanding. We assign a 60% probability of approval to envu in PsO and 20% probability of approval to envu in SLE. We do not ascribe value to sales of envu in psoriatic arthritis (PsA), although this indication should be viable given positive pivotal data for Sotyktu (deucravacitinib). We employ an 12% discount rate and 2% terminal growth rate.
Guggenheim
$18
Buy
331.65%
Upside
Initiated
06/10/25
Robert W. Baird
$25→$17
Buy
307.67%
Upside
Reiterated
02/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$29→$20
Buy
379.62%
Upside
Assigned
08/15/25
Wells Fargo
$17
Buy
307.67%
Upside
Reiterated
08/15/25
Morgan Stanley
$23→$22
Buy
427.58%
Upside
Reiterated
08/15/25
Cantor Fitzgerald
―
Buy
―
Reiterated
08/14/25
H.C. Wainwright
$14
Buy
235.73%
Upside
Reiterated
08/14/25
Alumis Inc.: Strong Buy Rating Backed by Promising Drug Candidate and Strategic PositioningValuation and Risks. Using a discounted cash flow (DCF)-based approach, we derive a firm value of $1.7B and a 12- month price objective of $14 per share, which includes the estimated end-2Q26 cash position of ~$262M and ~115M shares outstanding. We assign a 60% probability of approval to envu in PsO and 20% probability of approval to envu in SLE. We do not ascribe value to sales of envu in psoriatic arthritis (PsA), although this indication should be viable given positive pivotal data for Sotyktu (deucravacitinib). We employ an 12% discount rate and 2% terminal growth rate.
Guggenheim
$18
Buy
331.65%
Upside
Initiated
06/10/25
Robert W. Baird
$25→$17
Buy
307.67%
Upside
Reiterated
02/07/25
Best Analysts Covering Alumis Inc.
1 Month
xxx
Success Rate
2/5 ratings generated profit
Average Return
+3.24%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +3.24% per trade.
3 Months
xxx
Success Rate
2/9 ratings generated profit
Average Return
-18.00%
assigned a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 22.22% of your transactions generating a profit, with an average return of -18.00% per trade.
1 Year
Success Rate
2/9 ratings generated profit
Average Return
-31.93%
assigned a buy rating last month
Copying Thomas Smith's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -31.93% per trade.
2 Years
xxx
Success Rate
2/9 ratings generated profit
Average Return
-31.97%
assigned a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -31.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALMS Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
14
13
5
5
8
Buy
3
3
1
2
2
Hold
2
2
1
0
0
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
20
19
7
7
10
Each month's total comprises the sum of three months' worth of ratings.
ALMS Financial Forecast
ALMS Stock Forecast FAQ
What is ALMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Alumis Inc.’s 12-month average price target is 19.60.
What is ALMS’s upside potential, based on the analysts’ average price target?
Alumis Inc. has 370.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALMS a Buy, Sell or Hold?
Alumis Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Alumis Inc.’s price target?
The average price target for Alumis Inc. is 19.60. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $14.00. The average price target represents 370.02% Increase from the current price of $4.17.
The highest analyst price target is $25.00 ,the lowest forecast is $14.00. The average price target represents 370.02% Increase from the current price of $4.17.
What do analysts say about Alumis Inc.?
Alumis Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of ALMS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.